NCT00052832View on ClinicalTrials.gov

Doxercalciferol in Treating Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

September 30, 2002

Primary Completion Date

July 31, 2005

Conditions
LeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Diseases
Interventions
DIETARY_SUPPLEMENT

doxercalciferol

Trial Locations (1)

53792

University of Wisconsin Comprehensive Cancer Center, Madison

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Wisconsin, Madison

OTHER

NCT00052832 - Doxercalciferol in Treating Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia | Biotech Hunter | Biotech Hunter